Om

BioXcel Therapeutics Inc. is a biopharmaceutical company focused on neuroscience and immuno-oncology, using artificial intelligence-based approaches to identify and develop new medicines. Its current portfolio centers on IGALMI, a sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, and BXCL501, the company’s investigational neuropsychiatric candidate being studied across additional agitation-related and stress-related settings. The company also operates through its subsidiary OnkosXcel Therapeutics LLC, which supports work in immuno-oncology. Based in New Haven, Connecticut, BioXcel Therapeutics serves a specialized role in advancing treatments for acute behavioral and neurological conditions through targeted drug development and clinical research.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BIOXCEL THERAPEUTICS MED ENDAVU: Køb Bioxcel Therapeutics ($BX20) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Bioxcel Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.